PUBLISHER: Meticulous Research | PRODUCT CODE: 2132825
PUBLISHER: Meticulous Research | PRODUCT CODE: 2132825
Organ-on-Chip Market by Organ Type (Liver-on-Chip, Lung-on-Chip, Heart-on-Chip, Kidney-on-Chip, Brain-on-Chip, Gut-on-Chip, Skin-on-Chip), Type, Product & Service, Technology, Cell Source, Application, End User, and Geography - Global Forecast to 2036
The global organ-on-chip market was valued at USD 272.0 million in 2025 and is projected to reach USD 342.5 million in 2026. The market is expected to reach USD 2,543.2 million by 2036, registering a CAGR of 22.2% during the forecast period (2026-2036). This report provides a comprehensive assessment of the rapidly evolving organ-on-chip market by examining microphysiological systems, human-relevant preclinical models, alternatives to animal testing, organ-on-chip devices, drug discovery, toxicology testing, disease modeling, personalized medicine, regenerative medicine, competitive activities, and future growth opportunities.
Organ-on-chip technologies comprise microfluidic cell-culture devices engineered to replicate the structure, function, and physiological environment of human organs and tissues at a miniaturized scale. These platforms integrate microfluidic channels, cell-culture chambers, extracellular-matrix scaffolds, membrane systems, and embedded sensors to recreate organ-specific conditions such as fluid flow, mechanical strain, and cell-cell interfaces. By enabling researchers to investigate drug metabolism, toxicity, disease processes, and treatment response in human-relevant models, organ-on-chip systems address several limitations associated with conventional two-dimensional cell culture and animal models.
The market is being shaped by increasing demand for alternatives to animal testing, rising research and development costs in drug discovery, growing demand for human-relevant preclinical models, and expanding regulatory acceptance of microphysiological systems. The FDA Modernization Act 2.0, signed into law in December 2022, removed the longstanding requirement that certain drug safety and efficacy data be derived specifically from animal studies and explicitly recognized organ chips and microphysiological systems as qualifying alternatives. The agency subsequently published a roadmap setting out a phased reduction in animal testing, and the first full qualification package for an organ-on-chip technology was submitted under the ISTAND pathway in September 2026. The National Institutes of Health has invested substantially since 2012 through its Tissue Chip for Drug Screening program, and in June 2026 established a dedicated office to coordinate the development, validation, and application of human-based research methods.
This report delivers an in-depth analysis of the market by organ type, platform type, product and service, technology, cell source, application, end user, and geography. It evaluates the development of liver-on-chip, lung-on-chip, heart-on-chip, kidney-on-chip, brain-on-chip, gut-on-chip, skin-on-chip, multi-organ-on-chip, human-on-chip, tissue-on-chip, disease-on-chip, tumor-on-chip, organoid-based platforms, iPSC-based platforms, sensor-integrated platforms, imaging-integrated platforms, and AI-integrated platforms. The study also assesses the role of pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, hospitals, cosmetics companies, chemical companies, and government and regulatory organizations in shaping market growth.
Market Dynamics
The growing demand for alternatives to animal testing is one of the primary drivers of the organ-on-chip market. Scientific, ethical, and regulatory pressure to reduce dependence on animal models is encouraging pharmaceutical companies, biotechnology companies, research organizations, and regulatory bodies to evaluate human-relevant approaches. Organ-on-chip systems can reproduce aspects of human physiology, disease progression, drug metabolism, and toxicity in controlled experimental environments, creating opportunities for their use in preclinical testing and translational research.
Rising research and development costs in drug discovery are further accelerating market adoption. Pharmaceutical companies face high development costs and substantial late-stage clinical trial failure rates when conventional preclinical models fail to predict human responses. Organ-on-chip platforms can help identify safety and efficacy issues earlier in the development pipeline, potentially improving decision-making, reducing late-stage failures, and strengthening the economic case for human-relevant testing technologies.
Growing demand for human-relevant preclinical models is also supporting market growth. Traditional animal models may not accurately reproduce human physiology because of interspecies differences, while conventional two-dimensional cell cultures often lack the three-dimensional structure, mechanical forces, fluid flow, and cell-cell interactions found in living tissues. Organ-on-chip platforms use human-derived cells and engineered microenvironments to provide more physiologically relevant models for drug screening, disease modeling, pharmacokinetic studies, and toxicology.
Regulatory and public funding momentum is strengthening the market's commercial foundation. The FDA Modernization Act 2.0 opened a pathway for alternative preclinical approaches, while subsequent initiatives and guidance have increased attention to New Approach Methodologies, including organ-on-chip systems, advanced in vitro assays, and computational models. Comparable commitments in the European Union and the United Kingdom, together with sustained public funding for tissue-chip research, are supporting technology development, validation, standardization, and adoption.
Despite favorable conditions, the high cost of organ-on-chip platforms remains a significant restraint. Devices, instruments, consumables, specialized microfabrication, sensor integration, and human-cell sourcing can be considerably more expensive than conventional cell-culture methods. These costs may limit adoption among smaller biotechnology companies, academic laboratories, and research institutions operating with constrained budgets.
The lack of standardization is another important market challenge. Differences in materials, device designs, cell sources, experimental protocols, measurement methods, and data formats can make it difficult for end users to compare results across platforms. Limited standardization may also complicate the validation of organ-on-chip data as consistent, reproducible, and regulatory-grade evidence. Constrained supply of well-characterized human cells is a related limitation, with only a small proportion of cells procured for organ-on-chip research meeting the quality standards the application requires.
The market nevertheless presents substantial opportunities through the adoption of multi-organ-on-chip and human-on-chip platforms. Connected organ modules can support the study of inter-organ interactions, systemic drug metabolism, distribution, and toxicity, enabling more comprehensive representations of human physiology. The integration of artificial intelligence and machine learning for image analysis, data interpretation, automated monitoring, and predictive modeling is also creating opportunities to improve throughput, reduce manual analysis, and strengthen the predictive value of organ-on-chip experiments.
Segment Analysis
The report provides detailed market analysis across organ type, type, product and service, technology, cell source, application, end user, and geography, enabling stakeholders to identify high-growth opportunities and evolving trends in microphysiological systems, drug discovery, tissue engineering, precision medicine, and human-relevant research.
Based on organ type, the market is segmented into liver-on-chip, lung-on-chip, heart-on-chip, kidney-on-chip, brain-on-chip, gut-on-chip, skin-on-chip, bone and musculoskeletal-on-chip, pancreas-on-chip, tumor-on-chip, reproductive system-on-chip, and other organ types. Liver-on-chip is expected to account for the largest share of the market in 2026, reflecting the liver's central role in drug metabolism, the frequency with which hepatotoxicity terminates development programs, and the depth of validation and regulatory activity concentrated in hepatic applications. Tumor-on-chip is projected to register the highest CAGR during the forecast period, supported by the scale of oncology research expenditure and by the emergence of patient-specific therapy-selection applications alongside discovery and immuno-oncology screening.
Based on type, the market is segmented into single-organ-on-chip, multi-organ-on-chip, human-on-chip, tissue-on-chip, disease-on-chip, and tumor-on-chip. Single-organ-on-chip is expected to account for the largest share in 2026 because the questions the market currently pays to answer are organ-specific, and because simpler architectures deliver higher throughput, better reproducibility, and shorter validation pathways. Multi-organ-on-chip is projected to register the highest CAGR, driven by demand for metabolite-mediated toxicity assessment, systemic exposure modeling, and inter-organ signaling, and by the maturation of common media formulations and modular architectures.
Based on product and service, the market is segmented into products and services. Products include organ-on-chip devices, microfluidic chips, instruments, and consumables. Services include organ-on-chip testing, drug screening, toxicology testing, disease modeling, platform development, data analysis, and contract research. Products are expected to account for the larger share in 2026, reflecting the recurring consumable revenue generated by each installed platform. Services are projected to register the higher CAGR as smaller biotechnology companies and research organizations access specialized testing through contract research providers, and as sponsors seeking submission-grade data buy the study rather than the platform.
Based on technology, the market is segmented into microfluidic-based platforms, membrane-based platforms, hydrogel-based platforms, 3D bioprinting-based platforms, organoid-based platforms, iPSC-based platforms, sensor-integrated platforms, imaging-integrated platforms, and AI-integrated platforms. Microfluidic-based platforms are expected to account for the largest share in 2026 as the baseline architecture of the field, with the broadest application range and the most mature manufacturing base. AI-integrated platforms are projected to register the highest CAGR, reflecting the shift in the binding constraint from data generation to data interpretation and the explicit regulatory endorsement of pairing human-derived in vitro systems with computational modeling.
Based on cell source, the market is segmented into primary human cells, immortalized cell lines, stem cells, patient-derived cells, genetically engineered cells, and animal-derived cells. Primary human cells are expected to account for the largest share in 2026 on the strength of their functional fidelity and their status as the default reference material for human-relevance assessment. Genetically engineered cells are projected to register the highest CAGR, driven by isogenic comparison, reporter-based continuous readouts, falling editing costs, and the premium pricing that engineered material commands.
Based on application, the market is segmented into drug discovery and development, toxicology testing, disease modeling, personalized and precision medicine, regenerative medicine, cosmetic and personal care testing, chemical and environmental toxicology, and other applications. Toxicology testing is expected to account for the largest share in 2026 because it is the activity regulators specify, making demand increasingly non-discretionary, and because work conducted to Good Laboratory Practice standards commands a substantial premium. Personalized and precision medicine is projected to register the highest CAGR, supported by strengthening clinical correlation evidence for patient-derived models and by the larger denominator of clinical reimbursement.
Based on end user, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, hospitals and clinical institutions, cosmetics and personal care companies, chemical companies, government and regulatory organizations, and other end users. Pharmaceutical and biotechnology companies are expected to account for the largest share in 2026, reflecting their exposure to the cost of late-stage attrition, multi-site deployment, and consumable consumption well above research installations. Hospitals and clinical institutions are projected to register the highest CAGR as functional testing of patient-derived tissue moves toward routine use in treatment selection.
Regional Analysis
The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, covering 29 countries. Regional evaluations consider regulatory acceptance, public funding, pharmaceutical and biotechnology R&D, academic research, microfluidics, tissue engineering, organoid technologies, precision medicine, contract research, and investments influencing market growth.
North America is expected to account for the largest share of the global organ-on-chip market in 2026. The region's leadership is supported by the presence of leading organ-on-chip technology developers, sustained federal funding through the tissue chip program, strong pharmaceutical and biotechnology industries, and a regulatory environment that increasingly recognizes human-relevant preclinical models. The FDA Modernization Act 2.0, the agency's subsequent roadmap, and the ISTAND qualification pathway have strengthened the route for organ-on-chip data in drug-development submissions. Partnerships between pharmaceutical companies, technology developers, universities, and research institutes are further supporting market expansion.
Asia-Pacific is projected to register the highest CAGR during the forecast period. Growth is being driven by expanding pharmaceutical and biotechnology R&D investments, increasing academic research in microfluidics and tissue engineering, coordinated national programs in Japan, China, and South Korea, and growing interest in alternatives to animal testing. The region also holds a structural manufacturing advantage, since its semiconductor and precision molding industries provide capability directly applicable to the transition from lithographic prototyping to injection-molded device production. Increasing outsourcing to contract research organizations and the expansion of pharmaceutical research are expected to create additional opportunities across the region.
Europe is also expected to demonstrate strong market potential due to its established pharmaceutical industry, advanced biomedical research ecosystem, focus on animal-welfare alternatives, and investment in precision medicine, tissue engineering, and microphysiological systems. Germany, the United Kingdom, France, the Netherlands, Switzerland, Belgium, Sweden, Italy, and Spain are supporting research and commercialization through universities, biotechnology companies, research institutions, and pharmaceutical collaborations. The region hosts a disproportionate share of the world's platform developers relative to its pharmaceutical research base, and its emphasis on regulatory science and human-relevant models is expected to support wider adoption.
Latin America and the Middle East & Africa are expected to present emerging opportunities as pharmaceutical research, academic biotechnology, clinical research, and advanced life-sciences infrastructure expand. Market development in these regions will depend on funding availability, technology-transfer activities, specialized expertise, contract research capacity, and partnerships with global platform developers and research institutions. Increasing awareness of human-relevant models and the need to improve preclinical research outcomes are expected to support gradual market adoption.
Competitive Landscape
The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their organ models, microfluidic platforms, organ-on-chip devices, instruments, consumables, testing services, drug-screening services, toxicology services, disease-modeling services, platform development, data analysis, contract research, organoid-based platforms, iPSC-based platforms, sensor integration, imaging integration, AI integration, partnerships, acquisitions, geographic expansion initiatives, research and development investments, capacity expansion, product launches, and recent business developments.
Competitive benchmarking enables stakeholders to evaluate companies based on platform validation data, breadth of organ models, human-cell compatibility, ease of use, workflow integration, throughput, sensor capabilities, imaging, AI analytics, data quality, reproducibility, regulatory qualification progress, service capacity, pharmaceutical partnerships, and global market presence. Leading companies are expanding their portfolios from single-organ platforms toward multi-organ and human-on-chip systems, developing disease-specific and tumor models, integrating AI and digital biology, pursuing regulatory qualification pathways, and partnering with pharmaceutical companies to co-develop disease models and validate platform performance against clinical outcomes.
The global organ-on-chip market is fragmented in nature and is led by Emulate, Inc. (U.S.), MIMETAS B.V. (Netherlands), InSphero AG (Switzerland), and CN Bio Innovations Ltd. (U.K.). Key companies profiled in the report include Emulate, Inc. (U.S.), MIMETAS B.V. (Netherlands), CN Bio Innovations Ltd. (U.K.), TissUse GmbH (Germany), InSphero AG (Switzerland), Nortis, Inc. (U.S.), AlveoliX AG (Switzerland), Hesperos, Inc. (U.S.), Kirkstall Ltd. (U.K.), Cherry Biotech (France), AIM Biotech Pte. Ltd. (Singapore), the Northeastern University / Wyss Institute ecosystem (U.S.), SynVivo, Inc. (U.S.), Quris-AI (Israel), and Altis Biosystems, Inc. (U.S.).
How This Report Helps
- Provides accurate market size estimates and long-term forecasts for the global organ-on-chip market.
- Evaluates the impact of liver-on-chip, lung-on-chip, heart-on-chip, kidney-on-chip, brain-on-chip, gut-on-chip, skin-on-chip, multi-organ-on-chip, human-on-chip, tissue-on-chip, disease-on-chip, tumor-on-chip, organoid, iPSC, sensor-integrated, imaging-integrated, and AI-integrated platforms on market growth.
- Identifies high-growth opportunities across organ types, platform types, products and services, technologies, cell sources, applications, end users, and geographic regions.
- Analyzes emerging trends in alternatives to animal testing, microphysiological systems, human-relevant preclinical models, multi-organ platforms, human-on-chip systems, organoids, stem cells, patient-derived cells, AI, digital biology, precision medicine, toxicology, disease modeling, and regenerative medicine.
- Evaluates the influence of regulatory acceptance, the FDA Modernization Act 2.0, public tissue-chip funding, pharmaceutical R&D costs, clinical trial failure, animal-testing alternatives, standardization, platform validation, and contract research on industry development.
- Benchmarks leading companies based on platform validation, organ-model breadth, ease of use, workflow integration, cell-source capabilities, sensors, imaging, AI analytics, regulatory progress, pharmaceutical partnerships, research and development, and competitive positioning.
- Supports technology selection, platform development, organ-model strategy, drug-screening planning, toxicology testing, disease-modeling programs, precision-medicine research, contract research evaluation, investment decisions, partnership development, market entry, and business expansion strategies.
- Delivers actionable market intelligence for pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, hospitals and clinical institutions, cosmetics companies, chemical companies, government and regulatory organizations, platform developers, investors, and research partners.
Key Questions Answered
- What is the current size of the global organ-on-chip market, and how is it expected to evolve through 2036?
- What is the expected CAGR of the global organ-on-chip market during the forecast period?
- Which organ type, platform type, product and service, technology, cell-source, application, end-user, and regional segments are expected to account for the largest market shares during the forecast period?
- Which organ type, platform type, product and service, technology, cell-source, application, end-user, and regional segments are expected to experience the strongest growth?
- What are the major scientific, regulatory, pharmaceutical, technological, funding, and economic factors driving market growth?
- What are the major drivers, restraints, opportunities, and challenges influencing industry development?
- Which geographic markets present the most attractive business opportunities for organ-on-chip platform developers, pharmaceutical companies, contract research organizations, and research institutions?
- How are alternatives to animal testing, FDA and public funding initiatives, multi-organ platforms, human-on-chip systems, organoids, iPSC-based technologies, AI, and digital biology influencing the market?
- What are the major challenges facing the market, including high platform costs, lack of standardization, cell supply constraints, validation requirements, workflow integration, and regulatory qualification?
- Which emerging technologies are transforming the market, and how are microfluidics, membranes, hydrogels, 3D bioprinting, organoids, iPSCs, sensors, imaging, and AI being integrated into next-generation systems?
- Who are the leading companies operating in the market, and what organ-model, product, service, regulatory, pharmaceutical-partnership, investment, and competitive strategies are they adopting?
- What recent product launches, partnerships, collaborations, funding initiatives, validation studies, regulatory developments, and technological innovations are shaping the competitive landscape?
- How can stakeholders leverage market intelligence from this report to support platform development, drug discovery, toxicology testing, disease modeling, precision medicine, contract research, investment decisions, competitive benchmarking, market entry, and long-term business strategy?
TABLE OF CONTENTS
- Table of Contents
1. Introduction
- 1.1. Market Definition
- 1.2. Market Ecosystem
- 1.3. Currency and Limitations
- 1.3.1. Currency
- 1.3.2. Limitations
- 1.4. Key Stakeholders
2. Research Methodology
- 2.1. Research Approach
- 2.2. Data Collection & Validation Process
- 2.2.1. Secondary Research
- 2.2.2. Primary Research & Validation
- 2.2.2.1. Primary Interviews with Organ-on-Chip Experts
- 2.2.2.2. Country-/Region-Level Analysis
- 2.3. Market Estimation
- 2.3.1. Bottom-Up Approach
- 2.3.2. Top-Down Approach
- 2.3.3. Forecast Methodology
- 2.4. Data Triangulation
- 2.5. Assumptions for the Study
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Organ-on-Chip Technology Overview
- 4.2.1. Evolution from 2D Cell Culture to Organ-on-Chip
- 4.2.2. 3D Cell Culture
- 4.2.3. Organoids
- 4.2.4. Tissue-on-Chip
- 4.2.5. Organ-on-Chip
- 4.2.6. Human-on-Chip
- 4.2.7. Multi-Organ-on-Chip
- 4.3. Organ-on-Chip System Architecture
- 4.3.1. Microfluidic Channels
- 4.3.2. Cell Culture Chambers
- 4.3.3. Extracellular Matrix & Scaffolds
- 4.3.4. Membrane Systems
- 4.3.5. Sensors
- 4.3.6. Fluid Handling Systems
- 4.3.7. Pumps & Flow Controllers
- 4.3.8. Imaging Systems
- 4.3.9. Environmental Control Systems
- 4.3.10. Data Acquisition & Analysis Software
- 4.4. Market Dynamics
- 4.4.1. Drivers
- 4.4.1.1. Increasing Demand for Alternatives to Animal Testing
- 4.4.1.2. Rising R&D Costs in Drug Discovery
- 4.4.1.3. Growing Demand for Human-Relevant Preclinical Models
- 4.4.1.4. Increasing Adoption of 3D Cell Culture Technologies
- 4.4.1.5. Growing Pharmaceutical & Biotechnology R&D Investments
- 4.4.1.6. Increasing Applications in Personalized Medicine
- 4.4.1.7. Growing Regulatory Interest in Alternative Testing Methods
- 4.4.2. Restraints
- 4.4.2.1. High Cost of Organ-on-Chip Platforms
- 4.4.2.2. Lack of Standardization
- 4.4.2.3. Complex Experimental Workflows
- 4.4.2.4. Limited Availability of Skilled Professionals
- 4.4.2.5. Challenges in Reproducing Complete Human Physiology
- 4.4.3. Opportunities
- 4.4.3.1. Increasing Adoption of Multi-Organ-on-Chip Platforms
- 4.4.3.2. AI-Enabled Organ-on-Chip Analysis
- 4.4.3.3. Integration with Organoids
- 4.4.3.4. Increasing Adoption of Patient-Derived Cells
- 4.4.3.5. Expansion of Organ-on-Chip Applications in Clinical Research
- 4.4.3.6. Growth of Personalized & Precision Medicine
- 4.4.3.7. Increasing Adoption by Pharmaceutical Companies
- 4.4.3.8. Development of Regulatory-Grade Organ-on-Chip Models
- 4.4.4. Challenges
- 4.4.4.1. Reproducibility across Platforms
- 4.4.4.2. Long-Term Cell Viability
- 4.4.4.3. Standardization of Materials and Protocols
- 4.4.4.4. Validation Against Clinical Outcomes
- 4.4.4.5. Integration of Multiple Organs
- 4.4.1. Drivers
- 4.5. Technology Landscape
- 4.5.1. Microfluidics
- 4.5.2. 3D Cell Culture
- 4.5.3. Tissue Engineering
- 4.5.4. Biomaterials
- 4.5.5. Organotypic Cell Culture
- 4.5.6. Stem Cell Technologies
- 4.5.7. Induced Pluripotent Stem Cells
- 4.5.8. Organoid Integration
- 4.5.9. Biosensors
- 4.5.10. Real-Time Imaging
- 4.5.11. Artificial Intelligence & Machine Learning
- 4.5.12. Automated Organ-on-Chip Platforms
- 4.6. Organ-on-Chip Ecosystem
- 4.6.1. Organ-on-Chip Platform Manufacturers
- 4.6.2. Microfluidics Technology Providers
- 4.6.3. Cell & Tissue Suppliers
- 4.6.4. Reagent & Consumable Suppliers
- 4.6.5. Instrument Manufacturers
- 4.6.6. Pharmaceutical Companies
- 4.6.7. Biotechnology Companies
- 4.6.8. Contract Research Organizations
- 4.6.9. Academic & Research Institutions
- 4.6.10. Regulatory Organizations
- 4.7. Value Chain Analysis
- 4.7.1. Chip Design & Development
- 4.7.2. Materials & Microfabrication
- 4.7.3. Cell & Tissue Sourcing
- 4.7.4. Platform Manufacturing
- 4.7.5. System Integration
- 4.7.6. Application Development
- 4.7.7. Drug Testing & Research
- 4.7.8. Data Analysis & Interpretation
- 4.8. Regulatory & Standards Landscape
- 4.8.1. FDA Regulatory Landscape
- 4.8.2. European Regulatory Landscape
- 4.8.3. OECD Guidelines
- 4.8.4. Alternative Methods to Animal Testing
- 4.8.5. Good Laboratory Practice Requirements
- 4.8.6. Organ-on-Chip Standardization Initiatives
- 4.8.7. Ethical Considerations
- 4.9. Porter's Five Forces Analysis
- 4.9.1. Bargaining Power of Buyers
- 4.9.2. Bargaining Power of Suppliers
- 4.9.3. Threat of Substitutes
- 4.9.4. Threat of New Entrants
- 4.9.5. Degree of Competition
- 4.10. Investment & Industry Trends
- 4.10.1. Pharmaceutical Investments in Organ-on-Chip
- 4.10.2. Government Funding for Tissue Chip Research
- 4.10.3. Increasing Adoption of Human-on-Chip Platforms
- 4.10.4. Multi-Organ Platform Development
- 4.10.5. AI & Digital Biology Integration
- 4.10.6. Regulatory Acceptance of Organ-on-Chip
- 4.10.7. Partnerships Between Pharmaceutical Companies and Organ-on-Chip Developers
5. Organ-on-Chip Market, by Organ Type
- 5.1. Introduction
- 5.2. Liver-on-Chip
- 5.2.1. Hepatotoxicity Testing
- 5.2.2. Drug Metabolism
- 5.2.3. Drug-Induced Liver Injury
- 5.2.4. Liver Disease Modeling
- 5.3. Lung-on-Chip
- 5.3.1. Respiratory Disease Modeling
- 5.3.2. Pulmonary Toxicity
- 5.3.3. Drug Delivery Studies
- 5.3.4. Infectious Disease Modeling
- 5.4. Heart-on-Chip
- 5.4.1. Cardiotoxicity
- 5.4.2. Cardiac Disease Modeling
- 5.4.3. Drug Response Testing
- 5.5. Kidney-on-Chip
- 5.5.1. Nephrotoxicity
- 5.5.2. Kidney Disease Modeling
- 5.5.3. Drug Transport & Clearance
- 5.6. Brain-on-Chip
- 5.6.1. Neurotoxicity
- 5.6.2. Blood-Brain Barrier Modeling
- 5.6.3. Neurodegenerative Disease Modeling
- 5.6.4. Neurological Drug Development
- 5.7. Gut-on-Chip
- 5.7.1. Drug Absorption
- 5.7.2. Gastrointestinal Disease Modeling
- 5.7.3. Microbiome Studies
- 5.8. Skin-on-Chip
- 5.8.1. Dermatological Disease Modeling
- 5.8.2. Cosmetic Testing
- 5.8.3. Drug Permeation Studies
- 5.9. Bone & Musculoskeletal-on-Chip
- 5.10. Pancreas-on-Chip
- 5.11. Tumor-on-Chip
- 5.12. Reproductive System-on-Chip
- 5.13. Other Organ Types
6. Organ-on-Chip Market, by Type
- 6.1. Introduction
- 6.2. Single-Organ-on-Chip
- 6.3. Multi-Organ-on-Chip
- 6.4. Human-on-Chip
- 6.5. Tissue-on-Chip
- 6.6. Disease-on-Chip
- 6.7. Tumor-on-Chip
7. Organ-on-Chip Market, by Product & Service
- 7.1. Introduction
- 7.2. Products
- 7.2.1. Organ-on-Chip Devices
- 7.2.2. Microfluidic Chips
- 7.2.3. Instruments
- 7.2.3.1. Fluid Handling Systems
- 7.2.3.2. Pumps & Controllers
- 7.2.3.3. Incubation Systems
- 7.2.3.4. Imaging Systems
- 7.2.3.5. Sensors & Monitoring Systems
- 7.2.4. Consumables
- 7.2.4.1. Cell Culture Media
- 7.2.4.2. Reagents
- 7.2.4.3. Extracellular Matrix Materials
- 7.2.4.4. Assay Kits
- 7.2.4.5. Microfluidic Consumables
- 7.3. Services
- 7.3.1. Organ-on-Chip Testing Services
- 7.3.2. Drug Screening Services
- 7.3.3. Toxicology Testing Services
- 7.3.4. Disease Modeling Services
- 7.3.5. Platform Development Services
- 7.3.6. Data Analysis Services
- 7.3.7. Contract Research Services
8. Organ-on-Chip Market, by Technology
- 8.1. Introduction
- 8.2. Microfluidic-Based Platforms
- 8.3. Membrane-Based Platforms
- 8.4. Hydrogel-Based Platforms
- 8.5. 3D Bioprinting-Based Platforms
- 8.6. Organoid-Based Platforms
- 8.7. iPSC-Based Platforms
- 8.8. Sensor-Integrated Platforms
- 8.9. Imaging-Integrated Platforms
- 8.10. AI-Integrated Platforms
9. Organ-on-Chip Market, by Cell Source
- 9.1. Introduction
- 9.2. Primary Human Cells
- 9.3. Immortalized Cell Lines
- 9.4. Stem Cells
- 9.4.1. Embryonic Stem Cells
- 9.4.2. Induced Pluripotent Stem Cells
- 9.5. Patient-Derived Cells
- 9.6. Genetically Engineered Cells
- 9.7. Animal-Derived Cells
10. Organ-on-Chip Market, by Application
- 10.1. Introduction
- 10.2. Drug Discovery & Development
- 10.2.1. Target Validation
- 10.2.2. Drug Screening
- 10.2.3. Mechanism-of-Action Studies
- 10.2.4. Pharmacokinetics & Pharmacodynamics
- 10.2.5. Drug Efficacy Testing
- 10.3. Toxicology Testing
- 10.3.1. Drug Toxicity
- 10.3.2. Hepatotoxicity
- 10.3.3. Cardiotoxicity
- 10.3.4. Nephrotoxicity
- 10.3.5. Neurotoxicity
- 10.3.6. Pulmonary Toxicity
- 10.4. Disease Modeling
- 10.4.1. Cancer
- 10.4.2. Cardiovascular Diseases
- 10.4.3. Neurological Diseases
- 10.4.4. Respiratory Diseases
- 10.4.5. Gastrointestinal Diseases
- 10.4.6. Infectious Diseases
- 10.5. Personalized & Precision Medicine
- 10.5.1. Patient-Specific Disease Models
- 10.5.2. Treatment Response Prediction
- 10.5.3. Drug Selection
- 10.6. Regenerative Medicine
- 10.7. Cosmetic & Personal Care Testing
- 10.8. Chemical & Environmental Toxicology
- 10.9. Other Applications
11. Organ-on-Chip Market, by End User
- 11.1. Introduction
- 11.2. Pharmaceutical & Biotechnology Companies
- 11.3. Academic & Research Institutes
- 11.4. Contract Research Organizations
- 11.5. Hospitals & Clinical Institutions
- 11.6. Cosmetics & Personal Care Companies
- 11.7. Chemical Companies
- 11.8. Government & Regulatory Organizations
- 11.9. Other End Users
12. Organ-on-Chip Market, by Geography
- 12.1. Introduction
- 12.2. North America
- 12.2.1. U.S.
- 12.2.2. Canada
- 12.3. Europe
- 12.3.1. Germany
- 12.3.2. U.K.
- 12.3.3. France
- 12.3.4. Netherlands
- 12.3.5. Switzerland
- 12.3.6. Belgium
- 12.3.7. Sweden
- 12.3.8. Italy
- 12.3.9. Spain
- 12.3.10. Rest of Europe
- 12.4. Asia-Pacific
- 12.4.1. China
- 12.4.2. Japan
- 12.4.3. South Korea
- 12.4.4. India
- 12.4.5. Singapore
- 12.4.6. Australia
- 12.4.7. Taiwan
- 12.4.8. Rest of Asia-Pacific
- 12.5. Latin America
- 12.5.1. Brazil
- 12.5.2. Mexico
- 12.5.3. Argentina
- 12.5.4. Rest of Latin America
- 12.6. Middle East & Africa
- 12.6.1. Israel
- 12.6.2. UAE
- 12.6.3. Saudi Arabia
- 12.6.4. South Africa
- 12.6.5. Rest of Middle East & Africa
13. Competitive Landscape
- 13.1. Overview
- 13.2. Key Growth Strategies
- 13.3. Competitive Benchmarking
- 13.4. Competitive Dashboard
- 13.4.1. Market Leaders
- 13.4.2. Market Differentiators
- 13.4.3. Vanguards
- 13.4.4. Emerging Players
- 13.5. Market Share/Rank Analysis, by Key Player (2025)
- 13.5.1. Emulate, Inc. (u.s.)
- 13.5.2. Mimetas B.V. (netherlands)
- 13.5.3. Insphero AG (switzerland)
- 13.5.4. Cn Bio Innovations Ltd. (u.k.)
14. Company Profiles
- 14.1. Emulate, Inc.
- 14.1.1. Business Overview
- 14.1.2. Financial Overview
- 14.1.3. Organ-on-Chip Portfolio
- 14.1.4. Technology Capabilities
- 14.1.5. Strategic Developments
- 14.1.6. SWOT Analysis
- 14.2. MIMETAS B.V.
- 14.2.1. Business Overview
- 14.2.2. Financial Overview
- 14.2.3. Organ-on-Chip Portfolio
- 14.2.4. Technology Capabilities
- 14.2.5. Strategic Developments
- 14.2.6. SWOT Analysis
- 14.3. CN Bio Innovations Ltd.
- 14.3.1. Business Overview
- 14.3.2. Financial Overview
- 14.3.3. Organ-on-Chip Portfolio
- 14.3.4. Technology Capabilities
- 14.3.5. Strategic Developments
- 14.3.6. SWOT Analysis
- 14.4. TissUse GmbH
- 14.4.1. Business Overview
- 14.4.2. Financial Overview
- 14.4.3. Organ-on-Chip Portfolio
- 14.4.4. Technology Capabilities
- 14.4.5. Strategic Developments
- 14.4.6. SWOT Analysis
- 14.5. InSphero AG
- 14.5.1. Business Overview
- 14.5.2. Financial Overview
- 14.5.3. Organ-on-Chip Portfolio
- 14.5.4. Technology Capabilities
- 14.5.5. Strategic Developments
- 14.5.6. SWOT Analysis
- 14.6. Nortis, Inc.
- 14.6.1. Business Overview
- 14.6.2. Financial Overview
- 14.6.3. Organ-on-Chip Portfolio
- 14.6.4. Technology Capabilities
- 14.6.5. Strategic Developments
- 14.6.6. SWOT Analysis
- 14.7. AlveoliX AG
- 14.7.1. Business Overview
- 14.7.2. Financial Overview
- 14.7.3. Organ-on-Chip Portfolio
- 14.7.4. Technology Capabilities
- 14.7.5. Strategic Developments
- 14.7.6. SWOT Analysis
- 14.8. Hesperos, Inc.
- 14.8.1. Business Overview
- 14.8.2. Financial Overview
- 14.8.3. Organ-on-Chip Portfolio
- 14.8.4. Technology Capabilities
- 14.8.5. Strategic Developments
- 14.8.6. SWOT Analysis
- 14.9. Kirkstall Ltd.
- 14.9.1. Business Overview
- 14.9.2. Financial Overview
- 14.9.3. Organ-on-Chip Portfolio
- 14.9.4. Technology Capabilities
- 14.9.5. Strategic Developments
- 14.9.6. SWOT Analysis
- 14.10. Cherry Biotech
- 14.10.1. Business Overview
- 14.10.2. Financial Overview
- 14.10.3. Organ-on-Chip Portfolio
- 14.10.4. Technology Capabilities
- 14.10.5. Strategic Developments
- 14.10.6. SWOT Analysis
- 14.11. AIM Biotech Pte. Ltd.
- 14.11.1. Business Overview
- 14.11.2. Financial Overview
- 14.11.3. Organ-on-Chip Portfolio
- 14.11.4. Technology Capabilities
- 14.11.5. Strategic Developments
- 14.11.6. SWOT Analysis
- 14.12. Northeastern University / Wyss Institute Ecosystem
- 14.12.1. Overview
- 14.12.2. Institutional Overview and Funding
- 14.12.3. Technology Portfolio
- 14.12.4. Technology Capabilities and Commercial Translation
- 14.12.5. Strategic Developments
- 14.12.6. SWOT Analysis
- 14.13. SynVivo, Inc.
- 14.13.1. Business Overview
- 14.13.2. Financial Overview
- 14.13.3. Organ-on-Chip Portfolio
- 14.13.4. Technology Capabilities
- 14.13.5. Strategic Developments
- 14.13.6. SWOT Analysis
- 14.14. Quris-AI
- 14.14.1. Business Overview
- 14.14.2. Financial Overview
- 14.14.3. Organ-on-Chip Portfolio
- 14.14.4. Technology Capabilities
- 14.14.5. Strategic Developments
- 14.14.6. SWOT Analysis
- 14.15. Altis Biosystems, Inc.
- 14.15.1. Business Overview
- 14.15.2. Financial Overview
- 14.15.3. Organ-on-Chip Portfolio
- 14.15.4. Technology Capabilities
- 14.15.5. Strategic Developments
- 14.15.6. SWOT Analysis
15. Appendix
- 15.1. Related Reports
- 15.2. Customization Options
LIST OF TABLES
List of Tables
- Table 1. Global Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 2. Global Liver-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 3. Global Lung-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 4. Global Heart-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 5. Global Kidney-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 6. Global Brain-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 7. Global Gut-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 8. Global Skin-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 9. Global Bone & Musculoskeletal-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 10. Global Pancreas-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 11. Global Tumor-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 12. Global Reproductive System-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 13. Global Other Organ Types Organ-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 14. Global Organ-on-Chip Market, by Type, 2024-2036 (USD Million)
- Table 15. Global Single-Organ-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 16. Global Multi-Organ-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 17. Global Human-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 18. Global Tissue-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 19. Global Disease-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 20. Global Tumor-on-Chip Market, by Type, by Country/Region, 2024-2036 (USD Million)
- Table 21. Global Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 22. Global Organ-on-Chip Products Market, by Type, 2024-2036 (USD Million)
- Table 23. Global Organ-on-Chip Products Market, by Country/Region, 2024-2036 (USD Million)
- Table 24. Global Organ-on-Chip Devices Market, by Country/Region, 2024-2036 (USD Million)
- Table 25. Global Microfluidic Chips Market, by Country/Region, 2024-2036 (USD Million)
- Table 26. Global Organ-on-Chip Instruments Market, by Type, 2024-2036 (USD Million)
- Table 27. Global Organ-on-Chip Instruments Market, by Country/Region, 2024-2036 (USD Million)
- Table 28. Global Organ-on-Chip Consumables Market, by Type, 2024-2036 (USD Million)
- Table 29. Global Organ-on-Chip Consumables Market, by Country/Region, 2024-2036 (USD Million)
- Table 30. Global Organ-on-Chip Services Market, by Type, 2024-2036 (USD Million)
- Table 31. Global Organ-on-Chip Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 32. Global Organ-on-Chip Market, by Technology, 2024-2036 (USD Million)
- Table 33. Global Microfluidic-Based Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 34. Global Membrane-Based Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 35. Global Hydrogel-Based Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 36. Global 3D Bioprinting-Based Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 37. Global Organoid-Based Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 38. Global iPSC-Based Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 39. Global Sensor-Integrated Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 40. Global Imaging-Integrated Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 41. Global AI-Integrated Platforms Market, by Country/Region, 2024-2036 (USD Million)
- Table 42. Global Organ-on-Chip Market, by Cell Source, 2024-2036 (USD Million)
- Table 43. Global Organ-on-Chip Market for Primary Human Cells, by Country/Region, 2024-2036 (USD Million)
- Table 44. Global Organ-on-Chip Market for Immortalized Cell Lines, by Country/Region, 2024-2036 (USD Million)
- Table 45. Global Organ-on-Chip Market for Stem Cells, by Type, 2024-2036 (USD Million)
- Table 46. Global Organ-on-Chip Market for Stem Cells, by Country/Region, 2024-2036 (USD Million)
- Table 47. Global Organ-on-Chip Market for Patient-Derived Cells, by Country/Region, 2024-2036 (USD Million)
- Table 48. Global Organ-on-Chip Market for Genetically Engineered Cells, by Country/Region, 2024-2036 (USD Million)
- Table 49. Global Organ-on-Chip Market for Animal-Derived Cells, by Country/Region, 2024-2036 (USD Million)
- Table 50. Global Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 51. Global Organ-on-Chip Market for Drug Discovery & Development, by Country/Region, 2024-2036 (USD Million)
- Table 52. Global Organ-on-Chip Market for Toxicology Testing, by Type, 2024-2036 (USD Million)
- Table 53. Global Organ-on-Chip Market for Toxicology Testing, by Country/Region, 2024-2036 (USD Million)
- Table 54. Global Organ-on-Chip Market for Disease Modeling, by Type, 2024-2036 (USD Million)
- Table 55. Global Organ-on-Chip Market for Disease Modeling, by Country/Region, 2024-2036 (USD Million)
- Table 56. Global Organ-on-Chip Market for Personalized & Precision Medicine, by Country/Region, 2024-2036 (USD Million)
- Table 57. Global Organ-on-Chip Market for Regenerative Medicine, by Country/Region, 2024-2036 (USD Million)
- Table 58. Global Organ-on-Chip Market for Cosmetic & Personal Care Testing, by Country/Region, 2024-2036 (USD Million)
- Table 59. Global Organ-on-Chip Market for Chemical & Environmental Toxicology, by Country/Region, 2024-2036 (USD Million)
- Table 60. Global Organ-on-Chip Market for Other Applications, by Country/Region, 2024-2036 (USD Million)
- Table 61. Global Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 62. Global Organ-on-Chip Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2024-2036 (USD Million)
- Table 63. Global Organ-on-Chip Market for Academic & Research Institutes, by Country/Region, 2024-2036 (USD Million)
- Table 64. Global Organ-on-Chip Market for Contract Research Organizations, by Country/Region, 2024-2036 (USD Million)
- Table 65. Global Organ-on-Chip Market for Hospitals & Clinical Institutions, by Country/Region, 2024-2036 (USD Million)
- Table 66. Global Organ-on-Chip Market for Cosmetics & Personal Care Companies, by Country/Region, 2024-2036 (USD Million)
- Table 67. Global Organ-on-Chip Market for Chemical Companies, by Country/Region, 2024-2036 (USD Million)
- Table 68. Global Organ-on-Chip Market for Government & Regulatory Organizations, by Country/Region, 2024-2036 (USD Million)
- Table 69. Global Organ-on-Chip Market for Other End Users, by Country/Region, 2024-2036 (USD Million)
- Table 70. Global Organ-on-Chip Market, by Country/Region, 2024-2036 (USD Million)
- Table 71. North America: Organ-on-Chip Market, by Country, 2024-2036 (USD Million)
- Table 72. North America: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 73. North America: Organ-on-Chip Market, by Type, 2024-2036 (USD Million)
- Table 74. North America: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 75. North America: Organ-on-Chip Market, by Technology, 2024-2036 (USD Million)
- Table 76. North America: Organ-on-Chip Market, by Cell Source, 2024-2036 (USD Million)
- Table 77. North America: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 78. North America: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 79. U.S.: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 80. U.S.: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 81. U.S.: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 82. U.S.: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 83. Canada: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 84. Canada: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 85. Canada: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 86. Canada: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 87. Europe: Organ-on-Chip Market, by Country, 2024-2036 (USD Million)
- Table 88. Europe: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 89. Europe: Organ-on-Chip Market, by Type, 2024-2036 (USD Million)
- Table 90. Europe: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 91. Europe: Organ-on-Chip Market, by Technology, 2024-2036 (USD Million)
- Table 92. Europe: Organ-on-Chip Market, by Cell Source, 2024-2036 (USD Million)
- Table 93. Europe: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 94. Europe: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 95. Germany: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 96. Germany: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 97. Germany: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 98. Germany: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 99. U.K.: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 100. U.K.: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 101. U.K.: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 102. U.K.: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 103. France: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 104. France: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 105. France: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 106. France: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 107. Netherlands: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 108. Netherlands: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 109. Netherlands: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 110. Netherlands: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 111. Switzerland: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 112. Switzerland: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 113. Switzerland: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 114. Switzerland: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 115. Belgium: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 116. Belgium: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 117. Belgium: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 118. Belgium: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 119. Sweden: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 120. Sweden: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 121. Sweden: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 122. Sweden: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 123. Italy: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 124. Italy: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 125. Italy: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 126. Italy: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 127. Spain: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 128. Spain: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 129. Spain: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 130. Spain: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 131. Rest of Europe: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 132. Rest of Europe: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 133. Rest of Europe: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 134. Rest of Europe: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 135. Asia-Pacific: Organ-on-Chip Market, by Country, 2024-2036 (USD Million)
- Table 136. Asia-Pacific: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 137. Asia-Pacific: Organ-on-Chip Market, by Type, 2024-2036 (USD Million)
- Table 138. Asia-Pacific: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 139. Asia-Pacific: Organ-on-Chip Market, by Technology, 2024-2036 (USD Million)
- Table 140. Asia-Pacific: Organ-on-Chip Market, by Cell Source, 2024-2036 (USD Million)
- Table 141. Asia-Pacific: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 142. Asia-Pacific: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 143. China: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 144. China: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 145. China: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 146. China: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 147. Japan: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 148. Japan: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 149. Japan: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 150. Japan: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 151. South Korea: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 152. South Korea: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 153. South Korea: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 154. South Korea: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 155. India: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 156. India: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 157. India: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 158. India: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 159. Singapore: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 160. Singapore: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 161. Singapore: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 162. Singapore: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 163. Australia: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 164. Australia: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 165. Australia: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 166. Australia: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 167. Taiwan: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 168. Taiwan: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 169. Taiwan: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 170. Taiwan: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 171. Rest of Asia-Pacific: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 172. Rest of Asia-Pacific: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 173. Rest of Asia-Pacific: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 174. Rest of Asia-Pacific: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 175. Latin America: Organ-on-Chip Market, by Country, 2024-2036 (USD Million)
- Table 176. Latin America: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 177. Latin America: Organ-on-Chip Market, by Type, 2024-2036 (USD Million)
- Table 178. Latin America: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 179. Latin America: Organ-on-Chip Market, by Technology, 2024-2036 (USD Million)
- Table 180. Latin America: Organ-on-Chip Market, by Cell Source, 2024-2036 (USD Million)
- Table 181. Latin America: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 182. Latin America: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 183. Brazil: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 184. Brazil: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 185. Brazil: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 186. Brazil: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 187. Mexico: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 188. Mexico: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 189. Mexico: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 190. Mexico: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 191. Argentina: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 192. Argentina: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 193. Argentina: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 194. Argentina: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 195. Rest of Latin America: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 196. Rest of Latin America: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 197. Rest of Latin America: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 198. Rest of Latin America: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 199. Middle East & Africa: Organ-on-Chip Market, by Country, 2024-2036 (USD Million)
- Table 200. Middle East & Africa: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 201. Middle East & Africa: Organ-on-Chip Market, by Type, 2024-2036 (USD Million)
- Table 202. Middle East & Africa: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 203. Middle East & Africa: Organ-on-Chip Market, by Technology, 2024-2036 (USD Million)
- Table 204. Middle East & Africa: Organ-on-Chip Market, by Cell Source, 2024-2036 (USD Million)
- Table 205. Middle East & Africa: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 206. Middle East & Africa: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 207. Israel: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 208. Israel: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 209. Israel: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 210. Israel: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 211. UAE: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 212. UAE: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 213. UAE: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 214. UAE: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 215. Saudi Arabia: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 216. Saudi Arabia: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 217. Saudi Arabia: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 218. Saudi Arabia: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 219. South Africa: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 220. South Africa: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 221. South Africa: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 222. South Africa: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 223. Rest of Middle East & Africa: Organ-on-Chip Market, by Organ Type, 2024-2036 (USD Million)
- Table 224. Rest of Middle East & Africa: Organ-on-Chip Market, by Product & Service, 2024-2036 (USD Million)
- Table 225. Rest of Middle East & Africa: Organ-on-Chip Market, by Application, 2024-2036 (USD Million)
- Table 226. Rest of Middle East & Africa: Organ-on-Chip Market, by End User, 2024-2036 (USD Million)
- Table 227. Recent Developments, by Company (2024-2026)
- Table 228. Emulate, Inc.: Organ-on-Chip Portfolio
- Table 229. Emulate, Inc.: Strategic Developments
- Table 230. MIMETAS B.V.: Organ-on-Chip Portfolio
- Table 231. MIMETAS B.V.: Strategic Developments
- Table 232. CN Bio Innovations Ltd.: Organ-on-Chip Portfolio
- Table 233. CN Bio Innovations Ltd.: Strategic Developments
- Table 234. TissUse GmbH: Organ-on-Chip Portfolio
- Table 235. TissUse GmbH: Strategic Developments
- Table 236. InSphero AG: Organ-on-Chip Portfolio
- Table 237. InSphero AG: Strategic Developments
- Table 238. Nortis, Inc.: Organ-on-Chip Portfolio
- Table 239. Nortis, Inc.: Strategic Developments
- Table 240. AlveoliX AG: Organ-on-Chip Portfolio
- Table 241. AlveoliX AG: Strategic Developments
- Table 242. Hesperos, Inc.: Organ-on-Chip Portfolio
- Table 243. Hesperos, Inc.: Strategic Developments
- Table 244. Kirkstall Ltd.: Organ-on-Chip Portfolio
- Table 245. Kirkstall Ltd.: Strategic Developments
- Table 246. Cherry Biotech: Organ-on-Chip Portfolio
- Table 247. Cherry Biotech: Strategic Developments
- Table 248. AIM Biotech Pte. Ltd.: Organ-on-Chip Portfolio
- Table 249. AIM Biotech Pte. Ltd.: Strategic Developments
- Table 250. Northeastern University / Wyss Institute Ecosystem: Technology Portfolio
- Table 251. Northeastern University / Wyss Institute Ecosystem: Strategic Developments
- Table 252. SynVivo, Inc.: Organ-on-Chip Portfolio
- Table 253. SynVivo, Inc.: Strategic Developments
- Table 254. Quris-AI: Organ-on-Chip Portfolio
- Table 255. Quris-AI: Strategic Developments
- Table 256. Altis Biosystems, Inc.: Organ-on-Chip Portfolio
- Table 257. Altis Biosystems, Inc.: Strategic Developments
LIST OF FIGURES
List of Figures
- Figure 1. Organ-on-Chip Market Ecosystem
- Figure 2. Average Annual Currency Exchange Rates Against USD, 2024-2026
- Figure 3. Key Stakeholders in the Organ-on-Chip Market
- Figure 4. Research Process
- Figure 5. Secondary Sources Referenced for This Study
- Figure 6. Primary Research Techniques
- Figure 7. Key Executives Interviewed
- Figure 8. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
- Figure 9. Market Sizing and Growth Forecast Approach
- Figure 10. Global Organ-on-Chip Market, by Organ Type, 2026 Share and CAGR 2026-2036
- Figure 11. Global Organ-on-Chip Market, by Type, 2026 Share and CAGR 2026-2036
- Figure 12. Global Organ-on-Chip Market, by Product & Service, 2026 Share and CAGR 2026-2036
- Figure 13. Global Organ-on-Chip Market, by Technology, 2026 Share and CAGR 2026-2036
- Figure 14. Global Organ-on-Chip Market, by Application, 2026 Share and CAGR 2026-2036
- Figure 15. Global Organ-on-Chip Market, by End User, 2026 Share and CAGR 2026-2036
- Figure 16. Global Organ-on-Chip Market, by Cell Source, 2026 Share and CAGR 2026-2036
- Figure 17. Global Organ-on-Chip Market, by Geography
- Figure 18. Organ-on-Chip System Architecture
- Figure 19. Impact Analysis of Market Dynamics
- Figure 20. Organ-on-Chip Market Ecosystem Participants
- Figure 21. Organ-on-Chip Value Chain
- Figure 22. Porter's Five Forces Analysis, Organ-on-Chip Market
- Figure 23. Global Organ-on-Chip Market, by Organ Type, 2026 Share and CAGR 2026-2036
- Figure 24. Global Organ-on-Chip Market, by Type, 2026 Share and CAGR 2026-2036
- Figure 25. Global Organ-on-Chip Market, by Product & Service, 2026 Share and CAGR 2026-2036
- Figure 26. Global Organ-on-Chip Market, by Technology, 2026 Share and CAGR 2026-2036
- Figure 27. Global Organ-on-Chip Market, by Cell Source, 2026 Share and CAGR 2026-2036
- Figure 28. Global Organ-on-Chip Market, by Application, 2026 Share and CAGR 2026-2036
- Figure 29. Global Organ-on-Chip Market, by End User, 2026 Share and CAGR 2026-2036
- Figure 30. Global Organ-on-Chip Market Assessment, by Country/Region, 2026-2036 (USD Million)
- Figure 31. North America: Organ-on-Chip Market Snapshot
- Figure 32. Europe: Organ-on-Chip Market Snapshot
- Figure 33. Asia-Pacific: Organ-on-Chip Market Snapshot
- Figure 34. Key Growth Strategies Adopted by Leading Market Players (2024-2026)
- Figure 35. Organ-on-Chip Market: Competitive Benchmarking, by Offering
- Figure 36. Organ-on-Chip Market: Competitive Benchmarking, by Region
- Figure 37. Competitive Dashboard: Organ-on-Chip Market
- Figure 38. Global Organ-on-Chip Market Share Analysis, by Key Players (2025)
- Figure 39. Emulate, Inc.: Financial Snapshot
- Figure 40. Emulate, Inc.: SWOT Analysis
- Figure 41. MIMETAS B.V.: Financial Snapshot
- Figure 42. MIMETAS B.V.: SWOT Analysis
- Figure 43. CN Bio Innovations Ltd.: Financial Snapshot
- Figure 44. CN Bio Innovations Ltd.: SWOT Analysis
- Figure 45. TissUse GmbH: Financial Snapshot
- Figure 46. TissUse GmbH: SWOT Analysis
- Figure 47. InSphero AG: Financial Snapshot
- Figure 48. InSphero AG: SWOT Analysis
- Figure 49. Nortis, Inc.: Financial Snapshot
- Figure 50. Nortis, Inc.: SWOT Analysis
- Figure 51. AlveoliX AG: Financial Snapshot
- Figure 52. AlveoliX AG: SWOT Analysis
- Figure 53. Hesperos, Inc.: Financial Snapshot
- Figure 54. Hesperos, Inc.: SWOT Analysis
- Figure 55. Kirkstall Ltd.: Financial Snapshot
- Figure 56. Kirkstall Ltd.: SWOT Analysis
- Figure 57. Cherry Biotech: Financial Snapshot
- Figure 58. Cherry Biotech: SWOT Analysis
- Figure 59. AIM Biotech Pte. Ltd.: Financial Snapshot
- Figure 60. AIM Biotech Pte. Ltd.: SWOT Analysis
- Figure 61. Northeastern University / Wyss Institute Ecosystem: Funding Snapshot
- Figure 62. Northeastern University / Wyss Institute Ecosystem: SWOT Analysis
- Figure 63. SynVivo, Inc.: Financial Snapshot
- Figure 64. SynVivo, Inc.: SWOT Analysis
- Figure 65. Quris-AI: Financial Snapshot
- Figure 66. Quris-AI: SWOT Analysis
- Figure 67. Altis Biosystems, Inc.: Financial Snapshot
- Figure 68. Altis Biosystems, Inc.: SWOT Analysis
